ArticleInternational journal of emergency medicine2025
Usefulness of S100β protein in patients on antithrombotic drugs with mild traumatic brain injury: a prospective cohort study in an emergency department.
Article in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04305821 (Intérêt de la protéine S100β Dans Les Traumatismes Crâniens légers Sous Anti-Thrombotiques), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intérêt de la protéine S100β Dans Les Traumatismes Crâniens légers Sous Anti-Thrombotiques
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundS100β protein has interesting metrological characteristics in the general population with mild traumatic brain injury (TBI) but its value in the subpopulation of patients on antithrombotic drugs (ATD) remains poorly documented.
objectiveThe main objective was to evaluate the performance of S100β assay in ruling-out the presence of a cerebral injury after mTBI in subjects on ATD. DESIGN, SETTINGS AND
participantsThis prospective single-center study was conducted between March 2020 and September 2021 in the Emergency Department of a French hospital. Patients on ATD consulting for mTBI having occurred less than 6 h previously were included. OUTCOMES MEASURE AND ANALYSIS: The S100β assay was to have been performed within 6 h of the TBI, and a cut-off value of 0.105 µg/L was applied. The standard diagnosis was provided by cerebral computed tomography (CCT). The primary endpoint was the metrological qualities of S100β for detecting intracranial complication following TBI. Economic impact was evaluated as a secondary endpoint.
results245 patients were included, with a mean age of 81.5 (± 11.8) years. CCT showed cerebral injury for 15 (6.1%) patients. The S100β assay was negative for 58 (23.7%) patients. Sensitivity was 100% (95% CI: 78.2% − 100%), specificity 25.2% (95% CI: 19.7% − 31.3%), and NPV 100% (95% CI: 93.8% − 100%). The S100β assay could have avoided CCT for 23.7% of the subjects, which would save €82.03 per patient compared to the current strategy.
conclusionThe use of S100β within 6 h of a TBI among subjects on ATD is efficacious in safely discounting cerebral injury, with an appreciable economic saving. CLINICAL
trial registrationNCT04305821 (2020-03-09)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.